GNG7

GNG7 encodes the gamma-7 subunit of heterotrimeric G proteins and functions as a broadly acting tumor suppressor whose loss drives oncogenic signaling through multiple pathways. GNG7 physically interacts with mTOR to restrict its phosphorylation-dependent activation; FOXO3A directly binds the GNG7 promoter to maintain its expression, and loss of this axis causes adaptive mTOR reactivation that promotes aerobic glycolysis, proliferation, and survival in leukemia and colorectal cancer (PMID:37588187, PMID:41352746). GNG7 also interacts with RSPO3 to relay Akt/GSK-3β/β-catenin signaling that sustains gastric cancer stemness, and its overexpression suppresses Hedgehog pathway activation in lung adenocarcinoma (PMID:38581123, PMID:34635014). GNG7 is recurrently silenced in cancers through promoter hypermethylation, LOH, and post-transcriptional mechanisms including direct targeting by miR-19b-3p, miR-876-5p, and miR-6765-3p, as well as lncRNA/TARBP2-mediated mRNA decay (PMID:18219292, PMID:34635014, PMID:34221006, PMID:36230863, PMID:41352746).

1. 2008 Medium

   The first evidence that GNG7 is epigenetically silenced in cancer was established by demonstrating LOH and promoter hypermethylation in esophageal carcinoma, raising the question of whether GNG7 loss has functional consequences.

   Evidence LOH analysis, promoter methylation assay, and qRT-PCR in esophageal cancer cell lines and tissues

   PMID:18219292

   Open questions at the time

   • No functional rescue to show methylation reversal restores GNG7 activity
   • miR-328 regulation correlative only
   • Mechanism by which GNG7 loss promotes cancer not addressed
2. 2019 Medium

   GNG7 was placed mechanistically as a negative regulator of the mTOR pathway, answering the question of which signaling axis it controls: siRNA-mediated GNG7 silencing increased phosphorylation of mTOR, 4E-BP1, and p70S6K, and this was reversed by rapamycin.

   Evidence siRNA knockdown, western blot for mTOR pathway components, rapamycin rescue in rat trophoblast model

   PMID:30864685

   Open questions at the time

   • Physical interaction between GNG7 and mTOR not yet demonstrated
   • Rat trophoblast context may not generalize to cancer
   • Upstream transcriptional control of GNG7 unknown
3. 2020 Medium

   Upstream transcriptional control of GNG7 was partially resolved: FOXP1 represses GNG7 expression, and the miR-183/FOXP1 axis modulates GNG7 levels and mTOR-dependent trophoblast functions in preeclampsia.

   Evidence Gain/loss-of-function experiments, rescue experiments, functional cell assays in trophoblast model

   PMID:33139493

   Open questions at the time

   • Direct FOXP1 binding to GNG7 promoter not shown by ChIP
   • Relevance to cancer suppressor function of GNG7 not tested
   • FOXO3A as an activator not yet identified
4. 2021 Medium

   GNG7 was linked to Hedgehog pathway suppression in lung adenocarcinoma, broadening its downstream effector repertoire beyond mTOR, and miR-19b-3p was validated as a direct negative regulator of GNG7 mRNA.

   Evidence GNG7 overexpression/knockdown, Hedgehog pathway readouts, xenograft, rescue with GNG7 re-introduction

   PMID:34635014

   Open questions at the time

   • Physical interaction between GNG7 and Hedgehog pathway components not shown
   • Whether mTOR and Hedgehog suppression are independent functions unclear
5. 2021 Medium

   Two additional post-transcriptional silencing mechanisms were identified: miR-876-5p directly targets GNG7 in gastric cancer (sponged by CDR1as), and miR-146a indirectly reduces GNG7 in sebocytes, establishing that GNG7 is a convergent target of multiple miRNAs across tissues.

   Evidence Dual-luciferase reporter assays, miRNA mimic/inhibitor treatment, functional rescue, xenograft (gastric cancer); siRNA knockdown and lipid assays (sebocytes)

   PMID:34221006 PMID:34728702

   Open questions at the time

   • miR-146a effect on GNG7 is indirect — intermediate unknown
   • Whether GNG7 loss in sebocytes operates through mTOR not tested
6. 2022 Medium

   A non-miRNA post-transcriptional mechanism was identified: lncRNA LINC01526 recruits TARBP2 to GNG7 mRNA to accelerate its decay, providing the first evidence of RNA-binding-protein-mediated GNG7 silencing in gastric cancer.

   Evidence RNA immunoprecipitation for LINC01526-TARBP2 interaction, mRNA stability assay, rescue experiments, xenograft

   PMID:36230863

   Open questions at the time

   • Structural basis of TARBP2 recognition of GNG7 mRNA unknown
   • Whether TARBP2 acts endonucleolytically or recruits decay machinery not resolved
7. 2023 High

   Two key mechanistic questions were resolved: FOXO3A directly binds the GNG7 promoter (by ChIP), establishing the principal transcriptional activator, and GNG7 protein physically interacts with mTOR (by Co-IP), explaining how GNG7 restricts mTOR phosphorylation in AML.

   Evidence ChIP for FOXO3A at GNG7 promoter, Co-IP of GNG7-mTOR, phospho-mTOR western blot, shRNA knockdown, in vivo AML and PDX models

   PMID:37588187

   Open questions at the time

   • Binding domain on mTOR not mapped
   • Whether GNG7 competes with Raptor/Rictor for mTOR binding unknown
   • Structural basis of GNG7-mTOR complex not resolved
8. 2024 High

   GNG7 was found to physically interact with RSPO3 and relay Akt/GSK-3β/β-catenin signaling, revealing a second direct protein partner and a Wnt-related pro-stemness function, which paradoxically contrasts with its tumor-suppressive role via mTOR inhibition.

   Evidence Co-IP and LC-MS/MS identification of GNG7-RSPO3 interaction, epistasis by GNG7 knockdown blocking RSPO3-induced β-catenin, spheroid and in vivo peritoneal seeding models

   PMID:38581123

   Open questions at the time

   • How the same protein simultaneously suppresses mTOR and promotes β-catenin is unreconciled
   • Whether Gβγ complex formation is required for RSPO3 interaction unknown
   • Context-dependent tumor-suppressive vs. oncogenic roles not resolved
9. 2025 Medium

   The metabolic consequence of GNG7 loss was defined: GNG7 suppresses mTOR-driven aerobic glycolysis in colorectal cancer, and cancer-associated fibroblast-derived extracellular vesicles deliver miR-6765-3p to silence GNG7 in trans, linking tumor microenvironment communication to metabolic reprogramming.

   Evidence 3′-UTR luciferase reporter for miR-6765-3p/GNG7, GNG7 overexpression rescue of glycolysis, in vivo tumor model

   PMID:41352746

   Open questions at the time

   • Whether GNG7 affects glycolytic enzymes directly or solely via mTOR unknown
   • Single-study finding of EV-mediated miR-6765-3p delivery not independently replicated

• The structural basis of GNG7 interaction with mTOR and RSPO3, the requirement for Gβ dimerization in these interactions, and how GNG7 simultaneously suppresses mTOR while facilitating β-catenin activation remain unresolved.
• No structural data for GNG7-mTOR or GNG7-RSPO3 complexes
• Role of canonical Gβγ heterodimerization in tumor-suppressive function not tested
• Context-dependent pro- vs. anti-tumorigenic activities not mechanistically reconciled